Balancing Access and Value in Multi-Indication Medicines: Implications of PD-(L)1 Broad Listings in Australia
Isaiah Luc, Drew Carter, Tracy Merlin · 2026
Read Balancing Access and Value in Multi-Indication Medicines: Implications of PD-(L)1 Broad Listings in Australia by Isaiah Luc, Drew Carter, Tracy Merlin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13614983.txt.
Description
Isaiah Luc, Drew Carter, and Tracy Merlin analyse in 2026 a new Australian deal for cancer immunotherapy drugs that treat many kinds of cancer under one listing. Normally each use of such a drug is judged and priced on its own, which slows access and stacks up reviews. In 2025 the national advisory committee placed three drugs, nivolumab, ipilimumab, and pembrolizumab, under a single broad listing for advanced cancers, with one weighted-average price and rebate caps tied to use.
The authors weigh what this means for fairness, budgets, and clinic practice. A broad listing can speed patient access, cut review workload, and block price gaming between uses. Risks remain around paying fairly for uses of very different value. Other countries wrestling with multi-use medicines can learn from how Australia struck the balance.
Catalog record
| CREATOR | Isaiah Luc, Drew Carter, Tracy Merlin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28757 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |